Liquid Biopsy for RAS Screening in CRC: How Can We Successfully Implement This New Paradigm?

Slides:

Advertisements

Similar presentations

Molecular Testing of lung cancer in routine practice

Advertisements

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

What's New in Basal Insulin for Diabetes

Emerging Genomic Technologies: Extending the Application of Genomics to Prediction, Diagnosis, Monitoring, and Early Detection Luis A. Diaz, M.D. Johns.

Managing Colon cancer in the era of molecular markers

Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer CCO Independent Conference Highlights* of the.

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Exploring Early Combination Therapy in PAH

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Challenges in RAS Wild-Type mCRC

New ESMO Guidance on Tumor Sidedness in mCRC

Chronic Hepatitis C Virus Infection

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Starting Strong: Initial Evaluation of the Patient With HCV

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

Optimizing Outcomes in Short Bowel Syndrome With IF

What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Assessing the Impact: New Data in T790+ NSCLC

New Patient Journeys in Non-small cell lung cancer

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Regulatory Industry Statistics Workshop 2018

Colorectal Cancer: Current “Standard” Uses for Molecular Testing

Neoadjuvant Therapy in HER2-Positive Breast Cancer

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

Counseling Patients About Germline BRCA Mutations

Decision-making in the eRA of Treating to Target

Are We Closer to Personalized Medicine in MS?

Management Challenges in CLL

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.

KRAS, NRAS, PIK3CA Exon 20, and BRAF Genotypes in Synchronous and Metachronous Primary Colorectal Cancers Katharina Balschun, Jochen Haag, Ann-Kathrin.

Is RA Treatment Addressing the Real Needs of Patients?

Joanna Wang, Chetan Bettegowda The Journal of Molecular Diagnostics

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Figure 1 The dynamic nature of resistance mechanisms can be

Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR Marie.

Circulating tumor DNA: Solid data from liquid biopsies

Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

The Changing Field of Melanoma: Ipilimumab.

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Published online September 20, 2017 by JAMA Surgery

Practical Strategies to Guideline-Recommended Biomarker Testing in NSCLC.

Ashleigh C. McEvoy, Benjamin A. Wood, Nima M. Ardakani, Michelle R

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Optimizing Characterization of NSCLC Through Specialty Collaboration

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

New Insights on Treatment Strategies for mCRC:

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Raymond N. DuBois, M.D., Ph.D. Executive Director

Ali Shamseddine,MD,FRCP

Optimizing Outcomes in Patients With NSCLC and Liver Metastases

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Preoperative/neoadjuvant treatment of CRC liver metastases

Investigator Perspectives on the Current Utility of Validated and Emerging Biomarkers to Guide Treatment Decision-Making for Patients with Metastatic Colorectal.

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Next-Generation Sequencing and ctDNA

Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF Alois H. Lang, Heinz Drexel, Simone Geller-Rhomberg,

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.

Presentation transcript:

Liquid Biopsy for RAS Screening in CRC: How Can We Successfully Implement This New Paradigm?

Management Considerations in mCRC

RAS Testing and Use of EGFR Antibody Therapy

KRAS and NRAS Mutation Hotspots

RAS Mutation Prevalence: Geographic Variation

European Society of Pathology Quality Assessment of RAS Laboratory Testing

RAS Laboratory Testing: Effect of New Regulations After 1 Year

Liquid Biopsy

Testing for Circulating Tumor DNA

RAS Mutation Testing Using BEAMing PCR

Case Discussion: Background

Case Discussion: Abdominal CT

Case Discussion: Considerations in Assessing Metastatic Disease

Considerations for Molecular Testing

Considerations for Biopsy Source

Considerations for BRAF Testing

Case Discussion: First-line Therapy

Case Discussion: Second-line Therapy

Case Discussion: Considerations After Second-line Therapy

Case Discussion: Reassessment Using Liquid Biopsy

Potential Applications of Liquid Biopsy

Optimizing Use of Liquid Biopsy in Current Clinical Practice

Tissue-based vs Liquid Biopsy RAS Analysis: Pros and Cons

Mutation Testing: Need for Improved Analysis Time

Summary

Abbreviations

Abbreviations (cont)